{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Netherlands Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/nl/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/nl/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from Netherlands, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:d9f58c9bf0b10a0fadf326e5dabcd38376939a4346db8c1bb34e6b57eb2ee83c", "url": "https://www.nasdaq.com/articles/pharming-launches-joenja-japan-apds", "external_url": "https://www.nasdaq.com/articles/pharming-launches-joenja-japan-apds", "title": "Pharming Launches Joenja In Japan For APDS", "content_text": "(RTTNews) - Pharming Group (PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for adult and children aged 4 years and older with activated PI3K delta syndrome, following its inclusion in NHI price list. Activated PI3K delta syndrome (APDS) is a rare primary immunodeficiency caused by genetic variants in the PI3Kd (phosphoinositide 3-kinase delta) pathway, leading to recurrent infections, immune dysregulation, and increased risk of lymphoma. Joenja (leniolisib), and oral PI3Kd inhibitor, was approved based on results from a randomized, placebo-controlled Phase III trial that", "date_published": "2026-08-13T07:15:18+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "PHARM"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHARM", "name": "Pharming Group N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/a798bff4-517d-40b4-abac-a12327c0866c/"}]}}, {"id": "source:59021b4e1e561671d0ccd836e93f18b938cd9878fcbfc7478506c6d16f8492b4", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNQl84azZSa281dC1SaThtZ3M2ZFVkTTFWVGlRNWtwcDF0WlZBczl6djVsR3RfWWlpbGl5VlFtTU5YV1NZdGdJU1UtTDZxOW1lZGxqMlN2bkppblJKNzBJWERiRHo0TG93YTFYdjRqTHBRTmVubi16ZU5nR3V0WTlvQUNFNTRSZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNQl84azZSa281dC1SaThtZ3M2ZFVkTTFWVGlRNWtwcDF0WlZBczl6djVsR3RfWWlpbGl5VlFtTU5YV1NZdGdJU1UtTDZxOW1lZGxqMlN2bkppblJKNzBJWERiRHo0TG93YTFYdjRqTHBRTmVubi16ZU5nR3V0WTlvQUNFNTRSZw?oc=5", "title": "Pharming Group N.V.: Fundamentele analyse en financi\u00eble beoordelingen | PHARM | NL0010391025", "content_text": "Pharming Group N.V.: Fundamentele analyse en financi\u00eble beoordelingen | PHARM | NL0010391025", "date_published": "2021-05-08T23:24:30+00:00", "authors": [{"name": "MarketScreener Nederland"}], "tags": ["Market update", "PHARM"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHARM", "name": "Pharming Group N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/a798bff4-517d-40b4-abac-a12327c0866c/"}]}}, {"id": "source:dcaa96e3ebb1ca412618968f722645c8a50196d38bc655a49053ebfd386cd380", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPTWl2Q1E4RWpabXpvUlVYclZTNE11emQ2U2pRMzIweGZRWEIzWFZRMmRkMFpFRnUzNjVoUDcwbmhTbmNuVV9zSkdXUDJiRzVZX1BWVnRuSHNqMkpTWS03MExlMEQtNGdHVDBsREZEYktDYzdzUHlSTFE5by1sbms5bW9GTGEzcWxuTGVIakg1T2RvckU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPTWl2Q1E4RWpabXpvUlVYclZTNE11emQ2U2pRMzIweGZRWEIzWFZRMmRkMFpFRnUzNjVoUDcwbmhTbmNuVV9zSkdXUDJiRzVZX1BWVnRuSHNqMkpTWS03MExlMEQtNGdHVDBsREZEYktDYzdzUHlSTFE5by1sbms5bW9GTGEzcWxuTGVIakg1T2RvckU?oc=5", "title": "Vivoryon Therapeutics N.V.: koersdoel en analistenconsensus | VVY | NL00150002Q7", "content_text": "Vivoryon Therapeutics N.V.: koersdoel en analistenconsensus | VVY | NL00150002Q7", "date_published": "2021-05-06T07:48:48+00:00", "authors": [{"name": "MarketScreener Nederland"}], "tags": ["Market update", "VVY"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VVY", "name": "Vivoryon Therapeutics N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/ed225238-5523-4d1f-bb4d-bfcdc7607388/"}]}}]}